NCT06781242 Genotype-phenotype Relationship Between Cryptogenic Cholestasis and Familial Intrahepatic Cholestasis
| NCT ID | NCT06781242 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Cholestatic Liver Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-01-16 |
| Primary Completion | 2025-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2024-01-16 with a primary completion date of 2025-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Genotype-phenotype relationship between adult cryptogenic cholestasis and mutations in genes responsible for progressive familial intrahepatic cholestasis
Eligibility Criteria
Inclusion Criteria: * age ≥ 18 years * diagnosis of PFIC/CCLDs/HBCs * obtaining informed consent Exclusion Criteria: * Another documented cause of chronic liver disease capable of justifying the clinical phenotype
Contact & Investigator
Giovanni Vitale, MD
PRINCIPAL INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Frequently Asked Questions
Who can join the NCT06781242 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cholestatic Liver Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06781242 currently recruiting?
Yes, NCT06781242 is actively recruiting participants. Contact the research team at giovanni.vitale@aosp.bo.it for enrollment information.
Where is the NCT06781242 trial being conducted?
This trial is being conducted at Bologna, Italy, Modena, Italy.
Who is sponsoring the NCT06781242 clinical trial?
NCT06781242 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Giovanni Vitale, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 300 participants.